WCM Investment Management
IOVA icon

WCM Investment Management’s Iovance Biotherapeutics IOVA Stock Holding History

WCM Investment Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-184,731
Closed -$3.08M – 208
2022
Q1 		$3.08M Buy
184,731
+17,790
+11% +$275K 0.01% 157
2021
Q4 		$3.19M Buy
166,941
+14,940
+10% +$329K 0.01% 163
2021
Q3 		$3.75M Buy
152,001
+1,162
+0.8% +$27.4K 0.01% 151
2021
Q2 		$3.92M Buy
150,839
+83,694
+125% +$2.18M 0.01% 144
2021
Q1 		$2.13M Sell
67,145
-87,945
-57% -$3.65M 0.01% 149
2020
Q4 		$7.2M Sell
155,090
-57,327
-27% -$2.28M 0.02% 129
2020
Q3 		$6.99M Buy
212,417
+54,595
+35% +$1.67M 0.02% 117
2020
Q2 		$4.33M Sell
157,822
-36,316
-19% -$1.19M 0.02% 134
2020
Q1 		$5.81M Buy
194,138
+61,244
+46% +$1.62M 0.03% 93
2019
Q4 		$3.68M Buy
132,894
+111,611
+524% +$2.54M 0.02% 131
2019
Q3 		$387K Buy
+21,283
New +$471K ﹤0.01% 146

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

WCM Investment Management's IOVA Position: Q2 2022 in Review

WCM Investment Management sold out of Iovance Biotherapeutics (IOVA) in Q2 2022, closing a stake of 184,731 shares — an estimated $3.08M sold.

WCM Investment Management first reported a position in IOVA in Q3 2019 and held it in 11 quarters. The position peaked at $7.2M in Q4 2020. 237 funds tracked by Wall St. Rank hold IOVA as of Q2 2022.

  • WCM Investment Management reported no remaining Iovance Biotherapeutics position as of Q2 2022 after selling out during the quarter.
  • WCM Investment Management sold 184,731 Iovance Biotherapeutics shares in Q2 2022, an estimated $3.08M.
  • WCM Investment Management first reported a position in Iovance Biotherapeutics in Q3 2019 and held it in 11 quarters.
  • WCM Investment Management's Iovance Biotherapeutics position peaked at $7.2M in Q4 2020.
  • 237 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2022.

Based on WCM Investment Management's 13F filing for Q2 2022, filed 9 Aug 2022.